Angiography cannot differentiate between vulnerable and stable plaques, which inform clinicians about a patient’s risk of rupture. Immuno-imaging with SPECT/CT could be a route for marking increased immune response at the site of high-risk vulnerable plaques, but there remain some complications, according to a study published Jan. 21 in Molecular Imaging.

Navidea Biopharmaceuticals, producers of the amyloid PET agent NAV4694, announced Feb. 2 that CEO Mark Pikett, PhD, would hold a presentation at the 16th annual BIO CEO and Investor Conference taking place at the Waldorf Astoria in New York City, Feb. 10-11.

A comparison of PET/MR and PET/CT using a trimodality system showed that PET/MR is a worthy alternative, if not superior, to PET/CT when imaging for head and neck tumors, according to a study published Feb. 3 in in the Journal of Nuclear Medicine.

Four up-and-coming radiotracers to target areas of under-oxygenation, which indicates dying tissues and possible tumor proliferation, were compared and found to have similar biodistribution and uptake, according to a study published Feb. 3 in the Journal of Nuclear Medicine.

DioGenix announced Jan. 27 that preliminary research validates the company’s genetic sequencing assay, MSPrecise. The screening tool would identify people with multiple sclerosis (MS) in the very earliest stages of disease when symptoms are still subtle. 

OctreoPharm Sciences based in Berlin announced Jan. 29 that OPS202, an imaging agent for the detection of gastro-entero-pancreatic neuroendocrine tumors, received orphan drug designation from the European Medicines Agency.

Pain is unavoidable. It alerts sufferers to very real threats via injury and disease and is invaluable for that reason, but it is also vague and imprecise and sometimes just mysterious, especially in cases of chronic pain disorders. Stanford scientists sought to develop a biomarker that could visualize the molecular changes that signal pain generation and potentially use it to gauge wound healing and to assist in drug trials. 

Presurgical scanning for metastatic non-small cell lung cancer appears to lower incidence of unnecessary surgeries, according to an analysis published Jan. 21 in the Journal of Nuclear Medicine.